References
- George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060–4069.
- Murrin RJ, Murray JA. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev 2006;20:51–60.
- Caggiano V, Fernando LP, Schneider JM, Haesslein HC, Watson-Williams EJ. Thrombotic thrombocytopenic purpura: report of fourteen cases–occurrence during pregnancy and response to plasma exchange. J Clin Apher 1983;1:71–85.
- George JN, Vesely SK. Immune thrombocytopenic purpura–let the treatment fit the patient. N Engl J Med 2003;349:903–905.
- Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol 2007;136:649–655.
- George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–1935.
- Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004;44:1149–1158.
- Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60–68.
- Matzdorff AC. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;355:630; author reply 630.
- Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043–4049.
- Watanabe R, Shirai T, Tajima Y, Ohguchi H, Onishi Y, Fujii H, Takasawa N, et al. Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud’s syndrome. Intern Med 2010;49:1229–1232.